ONCOlog has filed for bankruptcy

Since the autumn of 2012, the Board of ONCOlog has worked to find buyers for the sale of the entire company or its assets. However, these efforts have not been successful and the ONCOlog Board has therefore not seen any alternative left but to apply for the company to be declared bankrupt.

Allenex owns 14.9% of ONCOlog, but has since mid-2011 changed its focus to include the transplantation area only. Allenex has since this strategic shift not financed ONCOlog in any way. Therefore, the ONCOlog bankruptcy will not have any effect on Allenex` financial results. This is due to the fact that the Allenex holding in ONCOlog is already valued at zero and that no other commitments exist.

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail: anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on May 08, 2013, at 12.45 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.


About Us

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED). The company’s largest owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. See www.linkmed.se for more information.

Documents & Links